同源康医药-B旗下阿散德替尼获国家药监局药品审评中心纳入优先审评品种名单_老虎社区_美港股上老虎

同源康医药-B旗下阿散德替尼获国家药监局药品审评中心纳入优先审评品种名单

美股速递01-29

同源康医药股份有限公司宣布，其研发的阿散德替尼（Asandeutertinib）已被中国国家药品监督管理局药品审评中心正式纳入优先审评品种名单。这一重要进展标志着该药物在临床价值和市场潜力方面获得了监管机构的高度认可。

优先审评资格的获得，将有望显著缩短阿散德替尼的审评审批时间，加速其在中国市场的上市进程，从而惠及更多患者。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1193030035?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-29 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193030035","market":"us","top_or_hot":-1,"title":"同源康医药-B旗下阿散德替尼获国家药监局药品审评中心纳入优先审评品种名单","media":"美股速递","content":"<p>同源康医药股份有限公司宣布，其研发的阿散德替尼（Asandeutertinib）已被中国国家药品监督管理局药品审评中心正式纳入优先审评品种名单。这一重要进展标志着该药物在临床价值和市场潜力方面获得了监管机构的高度认可。</p>\n<p>优先审评资格的获得，将有望显著缩短阿散德替尼的审评审批时间，加速其在中国市场的上市进程，从而惠及更多患者。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同源康医药-B旗下阿散德替尼获国家药监局药品审评中心纳入优先审评品种名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同源康医药-B旗下阿散德替尼获国家药监局药品审评中心纳入优先审评品种名单\n</h2>\n\n<h4 class=\"meta\">\n\n2026-01-29 17:16 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>同源康医药股份有限公司宣布，其研发的阿散德替尼（Asandeutertinib）已被中国国家药品监督管理局药品审评中心正式纳入优先审评品种名单。这一重要进展标志着该药物在临床价值和市场潜力方面获得了监管机构的高度认可。\n优先审评资格的获得，将有望显著缩短阿散德替尼的审评审批时间，加速其在中国市场的上市进程，从而惠及更多患者。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"","article_id":"1193030035","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193030035","pubTimestamp":1769678166,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"同源康医药股份有限公司宣布，其研发的阿散德替尼（Asandeutertinib）已被中国国家药品监督管理局药品审评中心正式纳入优先审评品种名单。这一重要进展标志着该药物在临床价值和市场潜力方面获得了监管机构的高度认可。\n优先审评资格的获得，将有望显著缩短阿散德替尼的审评审批时间，加速其在中国市场的上市进程，从而惠及更多患者。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02410":"同源康医药-B","BK1161":"生物科技"},"translate_title":"Asandetinib, a subsidiary of Tongyuankang Pharmaceutical-B, was included in the list of priority review varieties by the Drug Evaluation Center of the State Food and Drug Administration","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":1},"content_text":"同源康医药股份有限公司宣布，其研发的阿散德替尼（Asandeutertinib）已被中国国家药品监督管理局药品审评中心正式纳入优先审评品种名单。这一重要进展标志着该药物在临床价值和市场潜力方面获得了监管机构的高度认可。\n优先审评资格的获得，将有望显著缩短阿散德替尼的审评审批时间，加速其在中国市场的上市进程，从而惠及更多患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}